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Acquired muscular weakness and muscle wasting are
frequently observed in critically ill patients, especially after a
prolonged time in the intensive care unit (ICU).1 Patients with
severe pulmonary and/or abdominal infections are at in-
creased risk for intensive care unit-acquired weakness
(ICUAW), which may present as critical illness myopathy,
critical illness polyneuropathy, and/or their combination
—critical illness polyneuromyopathy.2,3 Both ICUAW and mus-
cle wasting are serious medical conditions, observed in up to
40% of respective patients.1,4 Current data indicate that
impaired weaning from mechanical ventilation and additional
neuromuscular dysfunction are frequent in patients with
severe abdominal infections.5 Despite aggressive medical
treatment, patients suffering from abdominal sepsis regularly
require prolonged treatment in the ICU; this can cause a
vicious cycle of prolonged bed rest and/or need for
sedation that contributes to pronounced ICUAW,
unfavourable clinical outcomes, and mortality rates remained
high for decades.6
More than two decades ago, single prediction scores such
as the ‘Acute Physiology And Chronic Health Evaluation’ II or
the ‘Mannheim Peritonitis Index’ were used to prognosticate
clinical outcomes in patients with severe peritonitis and
intra-abdominal sepsis.7 More recently, we have learned that
no single score can reliably predict outcomes in individuals
suffering from peritonitis and that complex patient-related
criteria and treatment-specific parameters should best define
the outcomes of affected ICU patients. For example, Petersen
et al. demonstrated in 2021 that outcome prediction in peri-
tonitis significantly increases when multiple patient-derived
factors and treatment-specific variables are integrated into
a multidomain prediction model.8
In patients suffering from critical illness, acute muscle
wasting often develops early (i.e. in the first few days of ICU
treatment) and is accelerated in the presence of additional
(multi-) organ dysfunction.9,10 Retrospective data indicate
that decreased muscle mass is a predictor of increased
in-hospital mortality in elderly patients with sepsis.11 In this
issue of the Journal of Cachexia, Sarcopenia, and Muscle,
Cox et al. provide important prospective data about the im-
pact of acute muscle mass loss and sarcopenia on long-term
outcome in critically ill patients with intra-abdominal sepsis.12
The authors included 47 ICU patients suffering from
intra-abdominal sepsis and followed them up for 1 year.
Abdominal computed tomography scans were performed to
assess skeletal muscle index.12 This study confirmed that loss
of muscle mass starts acutely and early in sepsis and persists
over time, leading to a considerable delay in clinical
recovery.12 The authors observed that pre-existing sarcopenia,
a condition which may be observed in a variety of chronic
illnesses, is a predictor of poor functional outcome and
increased mortality after 1 year.12 While this study focused
exclusively on patients with intra-abdominal sepsis, the results
are in line with other studies evaluating sarcopenia, thus
strengthening its value in predicting outcomes.13,14
The predictive synthesis of patient-related parameters
and treatment-specific criteria can be amplified by the
integration of molecular findings.15 Inexpensive cell-derived
biomarkers used to detect bacterial infection—such as the
delta-haemoglobin equivalent and granularity index—are
readily available and easily measured in a standard
laboratory.16 These simple lab tests, together with a
multidomain prediction model and CT scans for skeletal mus-
cle index measurement, could be integrated into a diagnostic/
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predictive arsenal, alerting clinicians to which peritonitis pa-
tients are at higher risk for adverse outcomes. While the acute
loss of muscle mass in patients suffering from abdominal
sepsis may be difficult to prevent, maximal therapy could be
tailored to individuals deemed ‘high risk’.17,18
Cachexia and sarcopenia have already been established as
risk factors for unfavourable clinical outcomes in chronic dis-
ease; we are however still gaining a better understanding of
the relevance of acute muscle loss in acute abdominal
sepsis. Cox et al. provide important additional prospective ev-
idence for putting this particular puzzle together. Sarcopenia
and muscle wasting are not just innocent bystanders in
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